NCT01696929View on ClinicalTrials.gov

An Open-Label Trial of Tocilizumab in Schizophrenia

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
Schizophrenia
Interventions
DRUG

Tocilizumab

"Therapeutic/Pharmacologic Class of Drug:~Tocilizumab is a recombinant humanized anti-human interleukin-6 (IL-6) receptor monoclonal antibody of the immunoglobulin (Ig) gamma-1 subclass.~Type of Dosage Form:~Concentrate for solution for infusion.~Route of Administration:~Intravenous (i.v.) infusion."

Trial Locations (1)

30912

Georgia Health Sciences University, Augusta

All Listed Sponsors
lead

Brian Miller

OTHER

NCT01696929 - An Open-Label Trial of Tocilizumab in Schizophrenia | Biotech Hunter | Biotech Hunter